Proof-of-concept trial of oregovomab in combination with TLR-3 agonists as first-line maintenance therapy for advanced ovarian cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2010
At a glance
- Drugs Oregovomab (Primary)
- Indications Ovarian cancer
- Focus Pharmacodynamics; Therapeutic Use
- 08 Apr 2010 New trial record